Skip to content

Advertisement

Translational Oncology

Global cancer occurrence has increased from 12.7 million new cases in 2008 to 14.1 million in 2012, and it is expected that the incidence will rise by around 70% over the next two decades. A comprehensive understanding of the pathophysiological processes underlying cancer development is of utmost importance for the development of detection techniques, diagnostic and prognostic markers, new therapies, risk assessment tools, and cancer prevention strategies.

Characterizing the molecular basis of cancer is a rapidly progressing area of research, with many laboratory discoveries translating into important advances that impact patient care. Our new cross-journal article collection on Translational Oncology aims to showcase the results of novel research findings that bridge the gap between basic science and cancer medicine.

The journals included in this collection are BMC Medicine, BMC Cancer, Cancers of the Head and Neck, Clinical Sarcoma Research and Journal of Experimental and Clinical Cancer Research. We are seeking submissions of research articles that provide important developments in cancer research. Preclinical studies should provide a significant advance in knowledge, and have clear potential for strong clinical impact. This collection will also include invited reviews, debates and commentaries. If you have any original research you would like us to consider for inclusion our Translational Oncology collection, please submit directly to your journal of choice, and state within your cover letter that you want the submission to be considered for this Translational Oncology article collection.

Guest Edited by Prof Tommaso Dragani (Fondazione IRCCS Istituto Nazionale dei Tumori, Italy), the series is now accepting submissions of research articles that provide important developments in cancer research. 

Please choose from the following list of journals to submit your article to:

Page 1 of 2
  1. Content type: Case report

    Synchronous squamous cell carcinoma of the head and neck (HNSCC) and non-Hodgkin’s lymphoma is a rare clinical scenario. It is unknown whether the R-CHOP chemotherapy for lymphoma would also be active against ...

    Authors: Ting Martin Ma, Hyunseok Kang, Steven P. Rowe and Ana P. Kiess

    Citation: Cancers of the Head & Neck 2018 3:2

    Published on:

  2. Content type: Research

    Docetaxel-based chemotherapy failure in advanced prostate carcinoma has partly been attributed to the resistance of prostate cancer (PC) cells to docetaxel-induced apoptosis. Hence, there is an urgent need to ...

    Authors: Zhan Yang, Jin-Suo Chen, Jin-Kun Wen, Hai-Tao Gao, Bin Zheng, Chang-Bao Qu, Kai-Long Liu, Man-Li Zhang, Jun-Fei Gu, Jing-Dong Li, Yan-Ping Zhang, Wei Li, Xiao-Lu Wang and Yong Zhang

    Citation: Journal of Experimental & Clinical Cancer Research 2017 36:178

    Published on:

  3. Content type: Research

    Dysregulation of miRNAs is associated with cancer development by coordinately suppressing abundant target genes. Emerging evidence indicates that miR-31 plays a dual role in tumorigenicity. However, whether mi...

    Authors: Yanping Gao, Jun Yi, Kai Zhang, Fan Bai, Bing Feng, Rui Wang, Xiaoyuan Chu, Longbang Chen and Haizhu Song

    Citation: Journal of Experimental & Clinical Cancer Research 2017 36:161

    Published on:

  4. Content type: Research

    Epigenetic abnormalities play important roles in nasopharyngeal cancer (NPC), however, the epigenetic changes associated with abnormal cell proliferation remain unclear.

    Authors: Jian Zhang, Xin Wen, Na Liu, Ying-Qin Li, Xin-Ran Tang, Ya-Qin Wang, Qing-Mei He, Xiao-Jing Yang, Pan-Pan Zhang, Jun Ma and Ying Sun

    Citation: Journal of Experimental & Clinical Cancer Research 2017 36:147

    Published on:

  5. Content type: Commentary

    Advances in deep sequencing technology have led to developments in personalized medicine. Here, we describe the implications of a recent investigation that sequenced ctDNA from the plasma of non-small cell lun...

    Authors: Clare Fiala and Eleftherios P. Diamandis

    Citation: BMC Medicine 2017 15:157

    Published on:

  6. Content type: Review

    Elucidation of mechanisms regulating bone metastasis has progressed significantly in recent years and this has translated to many new therapeutic options for patients with bone metastatic cancers. However, the...

    Authors: Andrew S. Gdowski, Amalendu Ranjan and Jamboor K. Vishwanatha

    Citation: Journal of Experimental & Clinical Cancer Research 2017 36:108

    Published on:

  7. Content type: Research

    Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, is a novel anticancer drug used for treating several types of cancers....

    Authors: Jin Wang, Xiaoyang Liu, Yongzhi Hong, Songtao Wang, Pin Chen, Aihua Gu, Xiaoyuan Guo and Peng Zhao

    Citation: Journal of Experimental & Clinical Cancer Research 2017 36:96

    Published on:

  8. Content type: Research article

    Metastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better clinical tools for prognostication as well as for prediction of response to treatment. Considerable inves...

    Authors: Alexander L. R. Lubbock, Grant D. Stewart, Fiach C. O’Mahony, Alexander Laird, Peter Mullen, Marie O’Donnell, Thomas Powles, David J. Harrison and Ian M. Overton

    Citation: BMC Medicine 2017 15:118

    Published on:

  9. Content type: Research article

    Despite an early response to platinum-based chemotherapy in advanced stage high-grade serous ovarian cancer (HGSOC), the majority of patients will relapse with drug-resistant disease. Aberrant epigenetic alter...

    Authors: Tushar Tomar, Nicolette G. Alkema, Leroy Schreuder, Gert Jan Meersma, Tim de Meyer, Wim van Criekinge, Harry G. Klip, Heidi Fiegl, Els van Nieuwenhuysen, Ignace Vergote, Martin Widschwendter, Ed Schuuring, Ate G. J. van der Zee, Steven de Jong and G. Bea A. Wisman

    Citation: BMC Medicine 2017 15:116

    Published on:

  10. Content type: Research article

    To evaluate a new UGT1A and DPYD polymorphism panel to better predict irinotecan-induced toxicity and the clinical response in Chinese patients with metastatic colorectal cancer (mCRC).

    Authors: Dan Liu, Jian Li, Jing Gao, Yanyan Li, Rui Yang and Lin Shen

    Citation: BMC Cancer 2017 17:437

    Published on:

  11. Content type: Research article

    A high rate of glycolysis leading to elevated lactate content has been linked to poor clinical outcomes in patients with head and neck and cervical cancer treated with radiotherapy. Although the biological exp...

    Authors: Eric Leung, Rob A. Cairns, Naz Chaudary, Ravi N. Vellanki, Tuula Kalliomaki, Eduardo H. Moriyama, Hilda Mujcic, Brian C. Wilson, Bradly G. Wouters, Richard Hill and Michael Milosevic

    Citation: BMC Cancer 2017 17:418

    Published on:

  12. Content type: Research article

    Cutaneous melanoma is the deadliest skin cancer, with an increasing incidence and mortality rate. Currently, staging of patients with primary melanoma is performed using histological biomarkers such as tumor t...

    Authors: Jasper Wouters, Miguel Vizoso, Anna Martinez-Cardus, F. Javier Carmona, Olivier Govaere, Teresa Laguna, Jesuchristopher Joseph, Peter Dynoodt, Claudia Aura, Mona Foth, Roy Cloots, Karin van den Hurk, Balazs Balint, Ian G. Murphy, Enda W. McDermott, Kieran Sheahan…

    Citation: BMC Medicine 2017 15:101

    Published on:

  13. Content type: Research article

    The androgen receptor (AR) is a major driver of prostate cancer, and increased AR levels and co-activators of the receptor promote the development of prostate cancer. INhibitor of Growth (ING) proteins target ...

    Authors: Arash Nabbi, Urszula L. McClurg, Subhash Thalappilly, Amal Almami, Mahsa Mobahat, Tarek A. Bismar, Olivier Binda and Karl T. Riabowol

    Citation: BMC Medicine 2017 15:103

    Published on:

  14. Content type: Research article

    Fibroblast growth factor receptors (FGFRs) are well-known proto-oncogenes in several human malignancies and are currently therapeutically targeted in clinical trials. Among glioma subtypes, activating FGFR1 al...

    Authors: Birgitta Lehtinen, Annina Raita, Juha Kesseli, Matti Annala, Kristiina Nordfors, Olli Yli-Harja, Wei Zhang, Tapio Visakorpi, Matti Nykter, Hannu Haapasalo and Kirsi J. Granberg

    Citation: BMC Cancer 2017 17:310

    Published on:

  15. Content type: Research article

    Endocrine therapy is standard treatment for estrogen receptor (ER)-positive breast cancer. However, its efficacy is limited by intrinsic and acquired resistance. Here the potential of S100β as a biomarker and ...

    Authors: Sara Charmsaz, Éamon Hughes, Fiona T. Bane, Paul Tibbitts, Marie McIlroy, Christopher Byrne, Sinéad Cocchiglia, Jean McBryan, Bryan T. Hennessy, Róisín M. Dwyer, Michael J. Kerin, Arnold D. Hill and Leonie S. Young

    Citation: BMC Medicine 2017 15:79

    Published on:

  16. Content type: Review

    Characterizing and monitoring tumor genomes with blood samples could achieve significant improvements in precision medicine. As tumors shed parts of themselves into the circulation, analyses of circulating tum...

    Authors: Samantha Perakis and Michael R. Speicher

    Citation: BMC Medicine 2017 15:75

    Published on:

  17. Content type: Research article

    Pancreatic adenocarcinomas (PAs) have very poor prognoses even when surgery is possible. Currently, there are no tissular biomarkers to predict long-term survival in patients with PA. The aims of this study we...

    Authors: S. Battini, F. Faitot, A. Imperiale, A. E. Cicek, C. Heimburger, G. Averous, P. Bachellier and I. J. Namer

    Citation: BMC Medicine 2017 15:56

    Published on:

  18. Content type: Review

    The development of resistance is a problem shared by both classical chemotherapy and targeted therapy. Patients may respond well at first, but relapse is inevitable for many cancer patients, despite many impro...

    Authors: Ian A. Cree and Peter Charlton

    Citation: BMC Cancer 2017 17:10

    Published on:

  19. Content type: Commentary

    Intra-tumour heterogeneity is a common molecular phenomenon in metastatic clear cell renal carcinoma (mRCC), representing the genetic complexity of a tumour with multiple metastatic sites. The present commenta...

    Authors: Viktoria Stühler and Jens Bedke

    Citation: BMC Medicine 2016 14:201

    Published on:

  20. Content type: Research

    Release of exosomes have been shown to play critical roles in drug resistance by delivering cargo. Targeting the transfer of exosomes from resistant cells to sensitive cells may be an approach to overcome some...

    Authors: Xiaohong Wang, Chengfeng Xu, Yitong Hua, Leitao Sun, Kai Cheng, Zhongming Jia, Yong Han, Jianli Dong, Yuzhen Cui and Zhenlin Yang

    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:186

    Published on:

  21. Content type: Research

    The integration of human papilloma virus (HPV) into host genome is one of the critical steps that lead to the progression of precancerous lesion into cancer. However, the mechanisms and consequences of such in...

    Authors: Jun-Wei Zhao, Fang Fang, Yi Guo, Tai-Lin Zhu, Yun-Yun Yu, Fan-Fei Kong, Ling-Fei Han, Dong-Sheng Chen and Fang Li

    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:180

    Published on:

  22. Content type: Commentary

    A blood test that can detect human malignancy with high clinical sensitivity and specificity is highly desirable. To achieve this, a tumor marker is needed that correlates with tumor burden and that can be mea...

    Authors: Vathany Kulasingam and Eleftherios P. Diamandis

    Citation: BMC Medicine 2016 14:186

    Published on:

  23. Content type: Research article

    Molecular intratumour heterogeneity (ITH) is common in clear cell renal carcinomas (ccRCCs). However, it remains unknown whether this is mirrored by heterogeneity of drug responses between metastases in the sa...

    Authors: Shanthini M. Crusz, Yen Zhi Tang, Shah-Jalal Sarker, Warner Prevoo, Irfan Kiyani, Luis Beltran, John Peters, Anju Sahdev, Axel Bex, Thomas Powles and Marco Gerlinger

    Citation: BMC Medicine 2016 14:185

    Published on:

Page 1 of 2